311
Participants
Start Date
May 17, 2016
Primary Completion Date
October 8, 2018
Study Completion Date
October 8, 2018
ABP 798
Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
Rituximab (US)
Supplied as a 10 mg/mL liquid concentrate for IV administration.
Rituximab (EU)
Supplied as a 10 mg/mL liquid concentrate for IV administration.
Research Site, Budapest
Research Site, Sofia
Research Site, Sofia
Research Site, Plovdiv
Research Site, Gyula
Research Site, Szentes
Research Site, Veszprém
Research Site, Szombathely
Research Site, Tallinn
Research Site, Berlin
Research Site, Berlin
Research Site, Duncansville
Research Site, Charlotte
Research Site, Orangeburg
Research Site, Summerville
Research Site, Edgewater
Research Site, Orlando
Research Site, Vero Beach
Research Site, Hialeah
Research Site, Aventura
Research Site, Tuscaloosa
Research Site, Memphis
Research Site, Magdeburg
Research Site, Flowood
Research Site, Lexington
Research Site, Lansing
Research Site, Tartu
Research Site, Bad Nauheim
Research Site, Oklahoma City
Research Site, Plano
Research Site, Mesquite
Research Site, Dallas
Research Site, League City
Research Site, Idaho Falls
Research Site, Las Vegas
Research Site, Thousand Oaks
Research Site, Upland
Research Site, Olympia
Research Site, Spokane
Research Site, Los Angeles
Research Site, Carrollton
Research Site, Poznan
Research Site, Poznan
Research Site, Poznan
Research Site, Bydgoszcz
Research Site, Krakow
Research Site, Wroclaw
Research Site, Lublin
Research Site, Warsaw
Research Site, Stalowa Wola
Research Site, Bialystok
Research Site, Gdansk
Research Site, Katowice
Research Site, Elblag
Research Site, Lodz
Lead Sponsor
Amgen
INDUSTRY